X
[{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"ARCA Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARCA biopharma and Oruka Therapeutics Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARCA biopharma and Oruka Therapeutics Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Oruka Therapeutics
Filters
Companies By Therapeutic Area
Details:
Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.
Lead Product(s):
ORKA-001
Therapeutic Area: Dermatology
Product Name: ORKA-001
Highest Development Status: IND Enabling
Product Type: Small molecule
Recipient:
ARCA Biopharma
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Merger
April 03, 2024
Details:
The net proceeds will be used to advance Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.
Lead Product(s):
ORKA-001
Therapeutic Area: Dermatology
Product Name: ORKA-001
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Fairmount
Deal Size: $275.0 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
April 03, 2024